Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance-Reference-Cited by-同舟云学术

Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance

Published:2024-07 Issue:7 Volume:5 Page:101611
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Vasilevska Jelena,Cheng Phil Fang,Lehmann Julia,Ramelyte Egle,Gómez Julia Martínez,Dimitriou Florentia,Sella Federica,Ferretti Daria,Salas-Bastos Adrian,Jordaan Whitney Shannon,Levesque Mitchell Paul,Dummer Reinhard,Sommer Lukas^ORCID

Funder

Swiss Cancer Research Foundation

Wilhelm Sander-Stiftung

Swiss National Science Foundation

Universität Zürich

CRC Health Group

Center for Cancer Research

Swiss Cancer League

Publisher

Elsevier BV

Reference67 articles.

1. A landscape of driver mutations in melanoma;Hodis;Cell,2012

2. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma;Krauthammer;Nat. Genet.,2012

3. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N. Engl. J. Med.,2015

4. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma;Dummer;J. Clin. Oncol.,2022

5. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials;Hauschild;JAMA Oncol.,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Was Melanome gegen Krebstherapie resistent macht;TumorDiagnostik & Therapie;2024-09